David F Bibby
Overview
Explore the profile of David F Bibby including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
272
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mbisa J, Lapp Z, Bibby D, Phillips L, Manso C, Packer S, et al.
J Infect Dis
. 2024 May;
230(6):e1254-e1262.
PMID: 38717937
Background: Hepatitis C virus (HCV) has high genetic diversity and is classified into 8 genotypes and >90 subtypes, with some endemic to specific world regions. This could compromise direct-acting antiviral...
2.
Singanayagam A, Moore C, Froude S, Celma C, Stowe J, Hani E, et al.
Euro Surveill
. 2023 Sep;
28(39).
PMID: 37768558
Enteroviruses are a common cause of seasonal childhood infections. The vast majority of enterovirus infections are mild and self-limiting, although neonates can sometimes develop severe disease. Myocarditis is a rare...
3.
Bradshaw D, Bibby D, Manso C, Piorkowska R, Mohamed H, Ledesma J, et al.
Clin Microbiol Infect
. 2021 Jul;
28(3):405-409.
PMID: 34245902
Objectives: We sought to evaluate clinically a hepatitis C virus (HCV) whole-genome, next-generation sequencing (NGS) pipeline that is agnostic to viral genotype. Methods: Performance of the NGS pipeline was assessed...
4.
Smith D, Bradshaw D, Mbisa J, Manso C, Bibby D, Singer J, et al.
J Viral Hepat
. 2021 May;
28(9):1256-1264.
PMID: 34003556
Sustained viral response (SVR) rates for direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection routinely exceed 95%. However, a small number of patients require retreatment. Sofosbuvir, velpatasvir and...
5.
Manso C, Bibby D, Lythgow K, Mohamed H, Myers R, Williams D, et al.
Front Microbiol
. 2020 Nov;
11:576572.
PMID: 33162957
Choice of direct acting antiviral (DAA) therapy for Hepatitis C Virus (HCV) in the United Kingdom and similar settings usually requires knowledge of the genotype and, in some cases, antiviral...
6.
Manso C, Bibby D, Mohamed H, Brown D, Zuckerman M, Mbisa J
Front Microbiol
. 2020 Sep;
11:1879.
PMID: 32903437
The long and expanding list of viral pathogens associated with causing encephalitis confounds current diagnostic procedures, and in up to 50% of cases, the etiology remains undetermined. Sequence-agnostic metagenomic next-generation...
7.
Mbisa J, Ledesma J, Kirwan P, Bibby D, Manso C, Skingsley A, et al.
J Antimicrob Chemother
. 2020 Jul;
75(11):3311-3318.
PMID: 32728703
Background: HIV treatment guidelines have traditionally recommended that all HIV-positive individuals are tested for evidence of drug resistance prior to starting ART. Testing for resistance to reverse transcriptase inhibitors and...
8.
Parkin N, Avila-Rios S, Bibby D, Brumme C, Eshleman S, Harrigan P, et al.
Viruses
. 2020 Jul;
12(7).
PMID: 32605062
Next-generation sequencing (NGS) is increasingly used for HIV-1 drug resistance genotyping. NGS methods have the potential for a more sensitive detection of low-abundance variants (LAV) compared to standard Sanger sequencing...
9.
Singer J, Thomson E, Hughes J, Aranday-Cortes E, McLauchlan J, da Silva Filipe A, et al.
Viruses
. 2019 Apr;
11(4).
PMID: 30987147
Using deep sequencing technologies such as Illumina's platform, it is possible to obtain reads from the viral RNA population revealing the viral genome diversity within a single host. A range...
10.
Hassan A, Bibby D, Mwaringa S, Agutu C, Ndirangu K, Sanders E, et al.
PLoS One
. 2019 Feb;
14(2):e0210559.
PMID: 30759103
Background: The epidemiology of HIV-1 drug resistance (HIVDR) determined by Sanger capillary sequencing, has been widely studied. However, much less is known about HIVDR detected using next generation sequencing (NGS)...